返回
Information Extraction from a Complex Multicomponent System by Target Factor Analysis
DOI:10.1021/ac901246x.png)
摘要
En 中文
A theoretical investigation into the mechanism of information extraction by target factor analysis (MA) is presented from experimental data in the form of a matrix, and the results were validated using composite spectra obtained by open-path Fourier transform-infrared (FT-IR) spectrometry. The composite spectra were generated by adding the spectral information of a target molecule with known path-integrated concentrations to the raw open-path FTIR spectra obtained in a pristine atmosphere. Target molecules are deemed to be detected when the weighted correlation coefficient between the calculated spectrum of the analyte and its reference spectrum exceeds 0.90. The effective detection by TFA is shown to depend on the variation of their concentrations over the period of the measurement and not necessarily on the magnitude of concentration. When TFA fails to detect an analyte at high, but relatively constant, concentration that varies so little as to have low variance, blank spectra, i.e., spectra in which the analyte is known to be absent, are included in the data matrix. This procedure effectively increases the variance of the concentrations in the whole data set, and TFA detects the analyte.
Keyword:
TRANSFORMATION FACTOR-ANALYSIS
TESTING FACTOR-ANALYSIS
MULTIVARIATE
SPECTROSCOPY
RESOLUTION
MIXTURES
KINETICS
SPECTRA
AI总结
对已上传原文的论文进行重点信息的提取,主要内容包括:简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
6.7
论文数:
4.7W
被引数:
15.9W
机构
引用论文
Combined kinetics and iterative target transformation factor analysis for spectroscopic monitoring of reactions
ANALYST
IF3.3
Resolution of mixture components by target transformation factor analysis and determinant analysis for the selection of targets
ANALYTICAL CHEMISTRY
IF6.7
Adsorption kinetics in binary surfactant mixtures studied with external reflection FTIR spectroscopy
Immunologic and Immunohistochemical Studies on Chronic Lymphocytic Thyroiditis with or without Thyroid Lymphoma
Oncology
IF0

